Cryptococcal Meningitis in AIDS

A large proportion of people with acquired immune deficiency syndrome contact cryptococcal meningitis. This opportunistic infection is associated with high mortality, particularly in resource-poor developing countries. The causative fungus, Cryptococcal neoformans, has a worldwide distribution. The clinical features of cryptococcal meningitis are not notably different from those of bacterial meningitis. Thus a high index of suspicion is critical for its diagnosis, particularly in areas of the world where standard medical laboratory facilities are difficult to come by. Prompt institution of effective and appropriate systemic antifungal drugs is also essential. This article discusses the mycology, clinical features, diagnosis and treatment of AIDSassociated cryptococcal meningitis.

[1]  G. Maartens,et al.  Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole , 2006, BMC infectious diseases.

[2]  L. Mofenson,et al.  Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. , 2004, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[3]  D. Banker,et al.  Cryptococcal meningitis in AIDS. , 2002, Indian journal of medical sciences.

[4]  Alimuddin Zumla,et al.  Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions , 2001, Postgraduate medical journal.

[5]  A. Grant,et al.  HIV infection and AIDS in the developing world , 2001, BMJ : British Medical Journal.

[6]  J. Perfect,et al.  Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  R. Herbrecht,et al.  Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability , 1999, Transplant infectious disease : an official journal of the Transplantation Society.

[8]  M. Saag,et al.  A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  F. Diaz,et al.  Management of elevated intracranial pressure in patients with Cryptococcal meningitis. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[10]  P. Reiss,et al.  Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS‐associated cryptococcal meningitis , 1997, AIDS.

[11]  M. Saag,et al.  Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. , 1997, The New England journal of medicine.

[12]  K. Tomecki Cryptococcosis in the era of AIDS 100 years after the discovery of Cryptococcus neoformans , 1997 .

[13]  Y. Coovadia,et al.  Cryptococcal meningitis in Durban, South Africa: a comparison of clinical features, laboratory findings, and outcome for human immunodeficiency virus (HIV)-positive and HIV-negative patients. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  S. Jaruratanasirikul Amphotericin B with or without flucytosine followed by fluconazole as primary therapy for cryptococcal meningitis in patients with AIDS. , 1996, The Southeast Asian journal of tropical medicine and public health.

[15]  R. Pollard,et al.  Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  T. G. Mitchell,et al.  Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans , 1995, Clinical microbiology reviews.

[17]  D. Dunt,et al.  Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  A. Casadevall,et al.  Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis , 1995, Infection and immunity.

[19]  M. Weinstein,et al.  Comparison of commercial kits for detection of cryptococcal antigen , 1994, Journal of clinical microbiology.

[20]  R. Rozenbaum,et al.  Clinical epidemiological study of 171 cases of cryptococcosis. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  A. Casadevall,et al.  False-negative cerebrospinal fluid cryptococcal latex agglutination tests for patients with culture-positive cryptococcal meningitis , 1993, Journal of clinical microbiology.

[22]  M. Saag,et al.  A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. , 1992, The New England journal of medicine.

[23]  M. Saag,et al.  Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. , 1992, The New England journal of medicine.

[24]  S. Levitz The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. , 1991, Reviews of infectious diseases.

[25]  D. Richman,et al.  A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. , 1991, The New England journal of medicine.

[26]  D. Ellis,et al.  Ecology, life cycle, and infectious propagule of Cryptococcus neoformans , 1990, The Lancet.

[27]  A. Forrestel,et al.  CRYPTOCOCCOSIS , 1982, The Lancet.

[28]  L. Mofenson,et al.  Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  S. T. Orton,et al.  Annual Meeting of the American Neurological Association , 2005, Psychiatric Quarterly.

[30]  Thomas S Harrison,et al.  Cryptococcal meningitis. , 2004, British medical bulletin.

[31]  D. Km,et al.  HIV infection and AIDS in the developing world. ABC of AIDS. , 2001 .

[32]  M. Saag,et al.  Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  M. Saag,et al.  Diagnosis and Management of Increased Intracranial Pressure in Patients with AIDS and Cryptococcal Meningitis , 2000 .

[34]  R. Larsen,et al.  Early mycological treatment failure in AIDS-associated cryptococcal meningitis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.